US20040058355A1 - Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor - Google Patents

Novel 21910, 56634, 55053, 2504, 15977, 14760, 25501, 17903, 3700, 21529, 26176, 26343, 56638, 18610, 33217, 21967, H1983, M1983, 38555 or 593 molecules and uses therefor Download PDF

Info

Publication number
US20040058355A1
US20040058355A1 US10/423,543 US42354303A US2004058355A1 US 20040058355 A1 US20040058355 A1 US 20040058355A1 US 42354303 A US42354303 A US 42354303A US 2004058355 A1 US2004058355 A1 US 2004058355A1
Authority
US
United States
Prior art keywords
protein
seq id
m1983
h1983
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/423,543
Inventor
Rosana Kapeller-Libermann
John Hunter
Rachel Meyers
Laura Rudolph-Owen
Rory Curtis
Peter Olandt
Fong-Ying Tsai
Katherine Galvin
Miyoung Chun
Mark Williamson
Inmaculada Silos-Santiago
Rajasekhar Bandaru
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to US16382198A priority Critical
Priority to US11758099P priority
Priority to US09/276,400 priority patent/US6140056A/en
Priority to US36516299A priority
Priority to US39218999A priority
Priority to US09/412,210 priority patent/US6403358B1/en
Priority to US09/448,076 priority patent/US6300092B1/en
Priority to US18606100P priority
Priority to US20068800P priority
Priority to US20544700P priority
Priority to US60892100A priority
Priority to US22192500P priority
Priority to US23503500P priority
Priority to US23492200P priority
Priority to US24666900P priority
Priority to US71121600A priority
Priority to US24832500P priority
Priority to US24889300P priority
Priority to US25751100P priority
Priority to US26016601P priority
Priority to US09/797,039 priority patent/US6730491B2/en
Priority to US84504401A priority
Priority to US09/909,743 priority patent/US20020151007A1/en
Priority to US09/920,346 priority patent/US20020081658A1/en
Priority to US09/928,531 priority patent/US20020086405A1/en
Priority to US09/929,218 priority patent/US20030096391A1/en
Priority to US31253901P priority
Priority to US09/963,159 priority patent/US20020077312A1/en
Priority to US10/008,016 priority patent/US20020173630A1/en
Priority to US10/012,055 priority patent/US20020164750A1/en
Priority to US10/003,690 priority patent/US6787345B1/en
Priority to US10/060,763 priority patent/US20030022286A1/en
Priority to US10/105,989 priority patent/US20030003477A1/en
Priority to US10/121,911 priority patent/US6607892B2/en
Priority to US10/217,168 priority patent/US6929938B2/en
Priority to US10/278,036 priority patent/US20030108934A1/en
Priority to US10/336,489 priority patent/US20030119147A1/en
Priority to US10/336,153 priority patent/US20030113790A1/en
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Priority to US10/423,543 priority patent/US20040058355A1/en
Assigned to MILLENNIUM PHARMACEUTICALS, INC. reassignment MILLENNIUM PHARMACEUTICALS, INC. ASSIGNMENT OF ASSIGNORS INTEREST (SEE DOCUMENT FOR DETAILS). Assignors: CHUN, MIYOUNG, KAPELLER-LIBERMANN, ROSANA, OLANDT, PETER J., SILOS-SANTIAGO, INMACULADA, CURTIS, RORY A.J., BANDARU, RAJASEKHAR, RUDOLPH-OWEN, LAURA A., TSAI, FONG-YING, GALVIN, KATHERINE M, HUNTER, JOHN J., MEYERS, RACHEL E., WILLIAMSON, MARK J.
Publication of US20040058355A1 publication Critical patent/US20040058355A1/en
Application status is Abandoned legal-status Critical

Links